Novartis is making a significant bet on antibody-drug conjugates (ADCs), paying $1.1 billion upfront to acquire Myricx Bio. The deal, announced Monday, signals a strategic push into a class of cancer therapies that combine tumor-targeting antibodies with potent cell-killing payloads.
The acquisition underscores the intensifying race among big pharma to secure ADCs, a technology that has produced blockbuster drugs like Enhertu and Kadcyla. Novartis, which has lagged behind rivals such as AstraZeneca and Pfizer in this space, is now seeking to catch up by integrating Myricx's early-stage pipeline.
The $1.1 billion upfront payment reflects the premium pharma companies are willing to pay for ADC candidates with novel mechanisms. Myricx's platform focuses on next-generation linker and payload technologies designed to improve efficacy while reducing side effects. Additional milestones could push the total deal value higher.
The acquisition positions Novartis to strengthen its oncology portfolio and compete more aggressively in the projected $20 billion-plus ADC market. For Myricx, the deal provides the resources to advance its pipeline through clinical development. The transaction is expected to close in the third quarter.
While analysts view the deal as strategically sound, some caution that ADCs remain technically challenging to develop, with a history of late-stage failures. The true test will come when Myricx's candidates enter clinical trials.